Examining personalized treatment for multiple sclerosis with rituximab and ocrelizumab

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study, known as ROS-MS, is a pharmacological substudy of the OVERLORD-MS study, which investigates the efficacy and safety of rituximab compared to ocrelizumab in treatment-naïve patients with relapsing-remitting multiple sclerosis. The study will quantify serum concentrations of both medications using advanced liquid chromatography tandem mass spectrometry at specific intervals. By analyzing these concentrations alongside biochemical parameters, researchers aim to explore the potential for personalized treatment approaches through therapeutic drug monitoring and pharmacokinetic-pharmacodynamic models. The overarching goal is to enhance treatment outcomes for patients with this condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Included in OVERLORD-MS (NCT04578639)
* Willing to attend laboratory for blood sample collection at scheduled time points

Exclusion criteria:

\* Not willing to attend laboratory for blood sample collection at scheduled time points

Where it's running

• Haukeland University Hospital, Deparment of medical biochemistry and pharmacology
  Bergen, Vestland, Norway Recruiting

Study contacts

• Principal investigator: Trond T. Serkland, M.D. — Haukeland University Hospital
• Study coordinator: Trond T. Serkland, M.D.
• Email: trond.tretteberg.serkland@helse-bergen.no
• Phone: 004755975563

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing Rituximab and Ocrelizumab for Relapsing-Remitting Multiple Sclerosis

  This study is testing whether rituximab can work just as well as ocrelizumab in helping people with relapsing-remitting multiple sclerosis manage their symptoms over two years.

  Recruiting at 9 sites Phase 3 Rennes University Hospital · Lyon, Bron and 22 other locations · NCT05758831

• People with Relapsing-Remitting MS try subcutaneous ocrelizumab at their clinic

  This study looks at how satisfied people with relapsing-remitting MS feel about receiving subcutaneous ocrelizumab in routine care.

  Recruiting at 2 sites Hoffmann-La Roche · Pardubice, Pardubice Region and 1 other locations · NCT07827586

• HiHat: Rituximab Followed by Cladribine in Relapsing-Remitting MS

  This trial tests whether giving rituximab and then cladribine in sequence is safe and doable for people with relapsing-remitting MS.

  Recruiting at 3 sites Phase 2 Uppsala University · Falun and 3 other locations · NCT07517185

• Comparing Rituximab and Ocrelizumab for Treating Relapsing Multiple Sclerosis

  This study is testing if rituximab works just as well as ocrelizumab for treating relapsing multiple sclerosis in adults.

  Recruiting Phase 3 Amsterdam UMC, location VUmc · Amsterdam · NCT05834855

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

• Chidamide, Lenalidomide, and Rituximab as induction therapy for newly diagnosed elderly or unfit double-expressor DLBCL

  This trial tests whether the combo of chidamide, lenalidomide, and rituximab can help treat newly diagnosed double-expressor DLBCL in people who are elderly or not fit for standard chemotherapy.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07884708

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.